Meticulous Research®, a leading global market research firm, has published a research report titled " Saudi Arabia Next Generation Sequencing (NGS) Market Size, Share, Forecast, and Trends Analysis by Offering (Sample Preparation (DNA Extraction, Library Preparation), Instruments) Type (SMRT, DNB) Application (Clinical, Research) End User-Forecast to 2031." According to the newest Meticulous Research® study, the Saudi Arabia NGS market is estimated to reach $50.0 million by 2031, growing at a CAGR of 10.1% between 2024 and 2031.

The rising number of cancer cases, rising pharmaceutical R&D expenditures, and an increase in genome mapping studies are all driving the growth of the Saudi Arabia NGS market. However, the high costs of NGS systems and consumables, data confidentiality concerns, the availability of alternative technologies, the low likelihood of detecting positive, actionable biomarkers, and ethical and legal difficulties associated to NGS-based diagnosis limit the growth of this industry.

Furthermore, increased adoption of NGS tools in hospitals and clinical laboratories, as well as government efforts supporting large-scale genome sequencing projects, are projected to provide potential possibilities for market players. However, some of the constraints limiting market growth include a dearth of experienced specialists, issues with data storage, management, interpretation, and confidentiality, as well as worries about regulatory requirements and consistency in diagnostic testing.

Key players in the Saudi Arabia NGS market include Illumina, Inc. (US), Thermo Fisher Scientific Inc. (US), F. Hoffmann-La Roche Ltd. (Switzerland), Revvity, Inc. (US), QIAGEN N.V. (Netherlands), Agilent Technologies, Inc. (US), Pacific Biosciences of California, Inc. (US), Danaher Corporation (US), Oxford Nanopore Technologies Plc. (UK), Beijing Genomics Institute (BGI) (China), and Bio-Rad Laboratories.
The Saudi Arabia NGS market is divided into four segments: Offering, Sequencing Type, Application, and End User.

In 2024, the consumables category is estimated to dominate the Saudi next-generation sequencing (NGS) market, accounting for 62.6%. This category contains both sample preparation and sequencing consumables. Library preparation and target enrichment solutions are expected to dominate the sample preparation market, accounting for 45%. These methods are critical for optimizing the whole library generation process, from DNA fragmentation and amplification to adapter ligation, enrichment, and barcoding. Their comprehensive character has made them extremely popular in clinical and research settings. Target enrichment, in example, allows researchers to focus on certain genes or genomic areas, reducing sequencing time and cost by eliminating extraneous data collection.

In terms of sequencing types, targeted genome sequencing is expected to be the top choice by 2024. This technique has various advantages, including reducing irrelevant genetic variation, which might confound clinical interpretation. It is also a less expensive option to whole genome (WGS) or whole exome sequencing (WES), particularly for big populations. Furthermore, targeted sequencing is important in pharmacogenomics, as it aids in the identification of gene-drug interactions and the development of extremely precise, gene-specific medicines.

In terms of applications, research and other scientific studies are estimated to account for 56.9% of the Saudi NGS market in 2024. This broad category encompasses cancer research, genetic illness research, cell and molecular biology, microbiology, infectious disease research, and agricultural science. Cancer research is expected to be the most significant, accounting for 49.4% of the category. This trend is being driven by the increasing incidence of cancer, the urgent need for breakthrough treatment alternatives, and the shift toward individualized medicines. NGS-based cancer tests have a significant advantage: they can replace several individual gene testing by assessing a diverse set of actionable indicators in a single run, saving time and resources.

Hospitals and diagnostic laboratories are expected to be the major customers of NGS technologies in Saudi Arabia by 2024. These institutions have greatly increased their usage of sequencing for clinical diagnostics, and this trend is projected to continue as the cost of NGS decreases. This expansion is also backed by Saudi Arabia's Vision 2030, which focuses on developing local genetic testing capabilities and updating diagnostic infrastructure through digital transformation. These projects make advanced genetic tools more available throughout the country's healthcare system.

Download Sample Report Here @ https://www.meticulousresearch.com/download-sample-report/cp_id=6002

Key Questions Answered in the Report:

·What is the revenue generated from the sales of NGS instruments, consumables, and software in Saudi Arabia?

·At what rate is the demand for NGS solutions & services projected to grow for the next five to seven years?

·What is the historical market size and growth rate for the Saudi Arabia NGS market?

·What are the major factors impacting the growth of the Saudi Arabia NGS market?

·What are the major opportunities for existing players and new entrants in the market?

·Which offering and end user segments are anticipated to create major traction for market players?

·What are the key trends in this market?

·Who are the major players in the Saudi Arabia NGS market? What are their specific offerings in this market?

·What recent developments have taken place in the Saudi Arabia NGS market? What are the impacts of these strategic developments on the market?

Contact Us:
Meticulous Research®
Email- [email protected]
Contact Sales- +1-646-781-8004
Connect with us on LinkedIn- https://www.linkedin.com/company/meticulous-research